AS1411, the first ssDNA aptamer to undergo clinical trials, proved to be safe and well tolerated in patients;47, 48 it can specifically target nucleolin, which is overexpressed in the cytoplasm and on membranes of various cancer cells, including AML.49 This evidence concerns the gene NUCLEOLIN and cancer.